Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Gastrointestinal Cancer

 

Regorafenib for Gastrointestinal Stromal Tumors (7390)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib

Investigator: Robin Jones;   Conditions: Gastrointestinal Cancer;    Status: Closed;   Study ID: NCT01271712

PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01839487

Veliparib for Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors

Investigator: Elizabeth Swisher, MD;   Conditions: High Grade Serous Ovarian Cancer, BRCA Mutated Breast Cancer;    Status: Closed;   Study ID: NCT01853306

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) Gastric or Gastroesophageal Junction Adenocarcinoma (20121103)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Investigator: Veena Shankaran;   Conditions: Gastrointestinal Cancer;    Status: Recruiting;   Study ID: NCT01697072